Are You Undervaluing These 3 Biopharmas' Pipelines?

The drugs in research and development at Gilead Sciences, Johnson & Johnson, and AbbVie could reward investors with multiple blockbuster wins in the coming years.

Biopharma companies are continously investing in new development projects to offset the risks of competition and patent expirations, but sometimes, the nature of business' landscape can keep investors from seeing opportunities that may be lurking in research-and-development pipelines. For instance, while challenges facing Gilead Sciences (NASDAQ:GILD), Johnson & Johnson (NYSE:JNJ), and AbbVie (NYSE:ABBV) shouldn't be ignored, each has compelling products under development that could send shares soaring someday.

No comments:

Post a Comment

Kraft Heinz Dividend Predictions Through 2023

Kraft-Heinz has excellent operating subsidiaries. The Heinz ketchup brand, launched shortly after the American Civil War, has a near mon...